DRUG DISCOVERY TODAY

MEDIA INFORMATION 2018

For more information visit:
www.drugdiscoverytoday.com
Why choose Drug Discovery Today?

We believe that we are unique from any other drug discovery periodical in that we have a blend of print and electronic products that give us the ability to provide a service to our readers and commercial customers that is unrivalled.

Drug Discovery Today, a peer-reviewed journal with reach

Drug Discovery Today is a fully peer-reviewed journal, well-respected in both industry and academia. It has been published since 1996 and contains high-quality review articles and editorials. All published reviews have been individually invited by the Editor, sometimes guided by suggestions from our excellent Editorial Board. The authors chosen to write articles are recognised experts in industry and academia. Our content has a broad and deep impact on the industry that is continuing to grow. The peer review process ensures consistent quality of our articles due to assessment by at least two external experts in addition to in-house review.

As a result of the quality content provided by Drug Discovery Today, we ensure a high quality readership from key individuals and decision-makers in drug discovery and development. This can be seen from the circulation breakdown provided in this media pack.

Drug Discovery Today, a unique innovative brand of products tailored to meet your needs

We have adapted: The Editorial team at Drug Discovery Today, in my opinion, is unlike any other catering for the drug discovery professional. First of all, we are responsive and flexible; we will work with you in a number of ways best to address your needs. We have shown our responsiveness in the ways we have reacted to industry changes over the last few years. A few years ago, we were effectively a print-based product, but since then we have combined with some of our other titles, to provide better coverage and have transitioned to become a digital publication. This allows greater functionality than we previously were able to offer.

With flexibility comes innovation: We now have a portfolio of integrated approaches, described in the pages of this media kit. Because we are flexible, we can discuss with you which combination of products would meet your objectives. We are introducing still more new products during 2018 for both the journal and website in response to comments from our readers, following our history of success from other such introductions.

We’re approachable: The Drug Discovery Today team is more than willing to talk and develop a turnkey solution to highlight your campaign.

However you decide to benefit from Drug Discovery Today, we are here to listen to what is driving your business.

With best regards,

Dr. Steve Carney
Editor, Drug Discovery Today
s.carney@elsevier.com
Our Subscribers

Elsevier circulates *Drug Discovery Today* to 7,578 qualified digital subscribers who requested the publication and met our strict circulation criteria.* Utilizing *Drug Discovery Today* and the journal’s associated products for your business objectives will ensure your message reaches our highly qualified global audience.

**Research Areas**

- Analytical Chemistry: 32%
- Assay Development: 35%
- Biochemistry: 35%
- Biotechnology: 16%
- Business Development: 24%
- Cell Biology: 28%
- Clinical Trials: 29%
- Endocrinology: 10%
- Genetics: 10%
- Genomics: 15%
- Immunology: 10%
- Informatics: 10%
- Medicinal Chemistry: 35%
- Microbiology: 28%
- Molecular Biology: 29%
- Neurosciences: 35%
- Patent Law: 28%
- Pharmaceuticals: 32%
- Pharmacology: 16%
- Pharmacy: 19%
- Physiology: 11%
- Proteomics: 16%
- Screening: 12%
- Structural Biology: 19%
- Synthetic Chemistry: 4%
- Toxicology: 4%
- Virology: 5%

**Research Techniques**

- Separation Technologies: 50%
- Capillary Electrophoresis: 28%
- Chromatography: 29%
- Electrophoresis: 9%
- Molecular Biology: 31%
- Cloning: 27%
- RT-PCR: 17%
- Bioinformatics: 27%
- Bioinformatics: 35%
- Mass Spectrometry/Spectroscopy: 32%
- Mass Spectrometry: 32%
- Spectroscopy: 28%
- Microscopy/Imaging Analysis: 23%
- Image Analysis: 35%
- Microscopy: 23%
- Gene Expression Analysis: 22%
- Gene Expression Analysis: 22%
- Microarray Analysis: 28%
- Cell/Tissue Culture: 20%
- Cell/Tissue Culture: 28%
- Laboratory Automation/HTS: 20%
- High Throughput Screening: 11%
- Robotics/Automation: 15%
- Proteomics: 14%
- Protein Isolation and Purification: 17%
- Protein-Protein Interaction Analysis: 17%
- Recombinant Protein Expression: 16%

**Geographical Coverage**

- Rest of World: 8%
- Asia-Pacific: 24%
- Europe: 36%
- North America: 32%

**Purchasing Budget**

- Less Than $10,000: 19%
- $10,000 – $50,000: 22%
- $50,000 – $100,000: 17%
- $100,000 – $250,000: 14%
- $250,000 – $500,000: 9%
- $500,000 – $1,000,000: 8%
- $1,000,000 – $2,000,000: 5%
- MORE THAN $2,000,000: 6%

* Based on December 2017 issue figures of 7,578 qualified subscribers. Publisher’s own data.

** Subscribers can choose multiple responses. Based on December 2017 issue figures of 7,578 qualified subscribers. Publisher’s own data.
Editorial Highlights

Drug Discovery Today is a fully peer reviewed and well-respected digital journal. Each issue will have its own focus section, comprising several articles on a specific theme.

We deliver highly current reviews to our readers from independent experts, not only addressing the rapid scientific developments in drug discovery associated technologies, but also the management, commercial and regulatory issues that increasingly play a part in how R&D is managed.

Our Website

Drug Discovery Today maintains a website dedicated to the field, www.drugdiscoverytoday.com. The website receives more than 10,000 views per month. In addition, Drug Discovery Today is on Elsevier’s ScienceDirect. Drug Discovery Today has had more than 800,000 downloads in 2017 from ScienceDirect.*

Editorial Calendar

<table>
<thead>
<tr>
<th>Month</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>Focus on Orphan Medicine</td>
</tr>
<tr>
<td>February</td>
<td>Focus on Cancer</td>
</tr>
<tr>
<td>March</td>
<td>Focus on Gene Editing</td>
</tr>
<tr>
<td>April</td>
<td>Special issue on Nanotherapeutic Strategies</td>
</tr>
<tr>
<td>May</td>
<td>Focus on Targeting Strategies</td>
</tr>
<tr>
<td>June</td>
<td>Focus on model systems</td>
</tr>
<tr>
<td>July</td>
<td>Focus on Nanocarriers</td>
</tr>
<tr>
<td>August</td>
<td>Focus on Drug Delivery</td>
</tr>
<tr>
<td>September</td>
<td>Focus on Formulation</td>
</tr>
<tr>
<td>October</td>
<td>Focus on Neurology</td>
</tr>
<tr>
<td>November</td>
<td>Focus on Medicinal Chemistry</td>
</tr>
<tr>
<td>December</td>
<td>Special issue on Synthetic Biology</td>
</tr>
</tbody>
</table>

Related Journals

Elsevier also publishes these journals related to drug discovery:
- Drug Discovery Today: Technologies
- Drug Discovery Today: Disease Models
- Regulatory Toxicology and Pharmacology
- International Journal of Pharmaceutics
- International Immunopharmacology
- European Journal of Pharmaceutical Sciences

* Publisher’s own data, December 2017
Editor’s Choice E-Newsletter

Drug Discovery Today Editor’s Choice E-Newsletter delivers highly current reviews to 22,670 readers worldwide every month, addressing the rapid scientific developments in drug discovery. Each issue has a specific theme, keeping our readers fully abreast of the latest trends and developments in drug discovery.

2018 Editor’s Choice Topics

<table>
<thead>
<tr>
<th>Month</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>Best of 2017</td>
</tr>
<tr>
<td>February</td>
<td>Medicinal Chemistry</td>
</tr>
<tr>
<td>March</td>
<td>Regulatory</td>
</tr>
<tr>
<td>April</td>
<td>Peptides</td>
</tr>
<tr>
<td>May</td>
<td>Cancer</td>
</tr>
<tr>
<td>June</td>
<td>Allosterism</td>
</tr>
<tr>
<td>July</td>
<td>Therapeutics</td>
</tr>
<tr>
<td>August</td>
<td>Novel Targets</td>
</tr>
<tr>
<td>September</td>
<td>Models</td>
</tr>
<tr>
<td>October</td>
<td>Drug Delivery</td>
</tr>
<tr>
<td>November</td>
<td>Nanotherapeutic Strategies</td>
</tr>
<tr>
<td>December</td>
<td>Informatics</td>
</tr>
</tbody>
</table>

Visit www.drugdiscoverytoday.com to review the latest issue of Editor’s Choice
Benefits of partnering with *Drug Discovery Today* for webinars

- **Position your company as a thought leader**
  Engage with researchers and scientific communities through compelling content around a relevant topic facing your audience.

- **Capture qualified leads**
  Benefit from our extensive experience to attract your target audience through a dedicated marketing campaign. Every registered delegate becomes a self-qualified sales lead. *Drug Discovery Today* readers are highly qualified and have purchasing authority.

- **Create significant brand awareness**
  Webinars are highly effective in reaching a large scientific audience through sponsorship. The *Drug Discovery Today* brand is trusted for its editorial integrity; the webinars will be moderated by the journal’s editor and co-branded by the journal.

- **Truly engage and interact with your audience**
  Receive immediate feedback via live Q&A and polls. Follow up on unanswered questions and generate dialogue post-event.

- **Receive tracking and reporting details within 48 hours**
  Our comprehensive lead reports show all viewer profiles and usage statistics, allowing your sales team to follow up with leads after the event.

- **Benefit from extended archiving**
  The webinar will be available on-demand following the live broadcast on both *Drug Discovery Today* and Elsevier websites, thus continuing to generate sales leads and delivering extended ROI.

---

**Editorial suggestions for webinar topics:**

- Synthetic biology
- Gene editing
- Antibiotic resistance
- Induced pluripotent cell lines
- Antibody-drug conjugates
- Big data
- Cocrystallisation
- In silico approaches to drug discovery
- Ocular delivery
- Rare and orphan diseases

To discuss any of the above webinar topics or suggest your own, please contact your sales representative.
### Advertising Rates and Specifications

#### Dates and Deadlines

<table>
<thead>
<tr>
<th>Issue</th>
<th>Jan</th>
<th>Feb</th>
<th>Mar</th>
<th>Apr</th>
<th>May</th>
<th>Jun</th>
<th>Jul</th>
<th>Aug</th>
<th>Sep</th>
<th>Oct</th>
<th>Nov</th>
<th>Dec</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad</td>
<td>28</td>
<td>29-</td>
<td>23</td>
<td>27</td>
<td>20</td>
<td>18</td>
<td>18</td>
<td>19</td>
<td>24</td>
<td>21</td>
<td>25</td>
<td>16</td>
</tr>
<tr>
<td>Close</td>
<td>Dec 17</td>
<td>Jan 18</td>
<td>Feb 15</td>
<td>Mar 18</td>
<td>Apr 18</td>
<td>May 18</td>
<td>Jun 18</td>
<td>Jul 18</td>
<td>Aug 18</td>
<td>Sep 18</td>
<td>Oct 18</td>
<td>Nov 18</td>
</tr>
</tbody>
</table>

#### Print advertising rates

<table>
<thead>
<tr>
<th>Position</th>
<th>US $</th>
<th>EUR €</th>
<th>GBP £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double Page Spread</td>
<td>$5,605</td>
<td>€3,995</td>
<td>£3,210</td>
</tr>
<tr>
<td>Full Page</td>
<td>$3,035</td>
<td>€2,060</td>
<td>£1,655</td>
</tr>
<tr>
<td>Half Page</td>
<td>$2,725</td>
<td>€1,160</td>
<td>£940</td>
</tr>
<tr>
<td>Quarter Page</td>
<td>$1,095</td>
<td>€750</td>
<td>£600</td>
</tr>
</tbody>
</table>

#### Special Positions

<table>
<thead>
<tr>
<th>Position</th>
<th>US $</th>
<th>EUR €</th>
<th>GBP £</th>
</tr>
</thead>
<tbody>
<tr>
<td>Covers and opposite contents</td>
<td>$770</td>
<td>€525</td>
<td>£420</td>
</tr>
<tr>
<td>Facing editorial</td>
<td>$435</td>
<td>€295</td>
<td>£235</td>
</tr>
</tbody>
</table>

#### Online advertising

<table>
<thead>
<tr>
<th>Website</th>
<th>Dimensions</th>
<th>Cost per month</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US $</td>
<td>EUR €</td>
</tr>
<tr>
<td>Leaderboard</td>
<td>728 x 90 pixels</td>
<td>$1,500</td>
</tr>
<tr>
<td>Skyscraper</td>
<td>120 x 600 pixels</td>
<td>$1,500</td>
</tr>
<tr>
<td>Large rectangle</td>
<td>336 x 280 pixels</td>
<td>$1,500</td>
</tr>
<tr>
<td>Button</td>
<td>150 x 100 pixels</td>
<td>$750</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-choice Alert</th>
<th>Dimensions</th>
<th>Cost per month</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>US $</td>
<td>EUR €</td>
</tr>
<tr>
<td>Leaderboard</td>
<td>468 x 60 pixels</td>
<td>$1,743</td>
</tr>
<tr>
<td>Button</td>
<td>150 x 100 pixels</td>
<td>$872</td>
</tr>
</tbody>
</table>

#### On-line file formats:

- Please include a url link for the creative
- Maximum file size 200KB
- Accepted file formats, jpg, gif, png and html5: https://support.google.com/richmedia/answer/2672542?hl=en-GB
Advertising Rates and Specifications

Print Advert Specifications

<table>
<thead>
<tr>
<th>Position</th>
<th>width x height (mm)</th>
<th>width x height (inches)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double Page Spread Trim Size</td>
<td>432mm x 280mm</td>
<td>17.007&quot; x 11.023&quot;</td>
</tr>
<tr>
<td>Double Page Spread Bleed</td>
<td>438mm x 286mm</td>
<td>17.244&quot; x 11.259&quot;</td>
</tr>
<tr>
<td>Full Page Trim Size</td>
<td>216mm x 280mm</td>
<td>8.503&quot; x 11.023&quot;</td>
</tr>
<tr>
<td>Full Page Bleed</td>
<td>222mm x 286mm</td>
<td>8.740&quot; x 11.259&quot;</td>
</tr>
<tr>
<td>Live/type area within Full Page (also applicable to DPS)</td>
<td>186mm x 250mm</td>
<td>7.323&quot; x 9.842&quot;</td>
</tr>
<tr>
<td>Half Page Horizontal</td>
<td>186mm x 120mm</td>
<td>7.323&quot; x 4.724&quot;</td>
</tr>
<tr>
<td>Half Page Vertical</td>
<td>88mm x 250mm</td>
<td>3.465&quot; x 9.842&quot;</td>
</tr>
<tr>
<td>Quarter Page Standard</td>
<td>88mm x 120mm</td>
<td>3.465&quot; x 4.724&quot;</td>
</tr>
</tbody>
</table>

Advert copy requirements

PDF
Adverts should be supplied as Composite PDF version 1.3, Please ensure that:
- Artwork is within CMYK colour space
- Image resolution is at least 300dpi
- Total ink coverage does not exceed 300%
- Fonts are embedded and subsetted
- Transparencies are flattened
- No colour management profiles should be included ie ICC profiles
- There should be no Multiple-Master fonts

Please note that:
- We cannot accept artwork in Microsoft product formats.
- Overprint and knockout is the responsibility of the originator. If your requirements are outside of typical printer default settings (100% black set to overprint and 100% white set to knockout) you must inform us.
- We cannot accept responsibility for colour without a contract proof

Digital Edition enhanced advertising

Rich media

For technical requirements for embedded audio or video files, please contact us.

Method of supply

Please email your advertisement to adcopy@elsevier.com
Contacts

Contact your sales representative and find out how Drug Discovery Today will help achieve your company’s promotional goals:

Kevin Partridge  
+44 (0)1865 843 717  
k.partridge@elsevier.com

Elsevier addresses:

**USA**  
Elsevier  
230 Park Avenue  
New York, NY 10169  
USA  
E-mail: adcopy@elsevier.com  
Tel: +44 1865 843687

**UK**  
Elsevier  
The Boulevard  
Langford Lane, Kidlington  
Oxford OX5 1GB  
United Kingdom  
E-mail: adcopy@elsevier.com  
Tel: +44 1865 843687

**Europe & ROW**  
Elsevier  
Radarweg 29  
1043 NX Amsterdam  
The Netherlands  
E-mail: adcopy@elsevier.com  
Tel: +44 1865 843687
MEDIA INFORMATION 2018

For more information visit:
www.drugdiscoverytoday.com